| Title: |
MiR-662 is associated with metastatic relapse in early-stage breast cancer and promotes metastasis by stimulating cancer cell stemness |
| Authors: |
Puppo M.; Valluru M. K.; Croset M.; Ceresa D.; Iuliani M.; Khan A.; Wicinski J.; Charafe-Jauffret E.; Ginestier C.; Pantano F.; Ottewell P. D.; Clézardin P. |
| Contributors: |
Puppo, M.; Valluru, M. K.; Croset, M.; Ceresa, D.; Iuliani, M.; Khan, A.; Wicinski, J.; Charafe-Jauffret, E.; Ginestier, C.; Pantano, F.; Ottewell, P. D.; Clézardin, P. |
| Publisher Information: |
SPRINGERNATURE; CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND |
| Publication Year: |
2023 |
| Collection: |
Università degli Studi di Genova: CINECA IRIS |
| Description: |
BackgroundBreast cancer (BC) metastasis, which often occurs in bone, contributes substantially to mortality. MicroRNAs play a fundamental role in BC metastasis, although microRNA-regulated mechanisms driving metastasis progression remain poorly understood.MethodsMiRome analysis in serum from BC patients was performed by TaqMan & TRADE; low-density array. MiR-662 was overexpressed following MIMIC-transfection or lentivirus transduction. Animal models were used to investigate the role of miR-662 in BC (bone) metastasis. The effect of miR-662-overexpressing BC cell conditioned medium on osteoclastogenesis was investigated. ALDEFLUOR assays were performed to study BC stemness. RNA-sequencing transcriptomic analysis of miR-662-overexpressing BC cells was performed to evaluate gene expression changes.ResultsHigh levels of hsa-miR-662 (miR-662) in serum from BC patients, at baseline (time of surgery), were associated with future recurrence in bone. At an early-stage of the metastatic disease, miR-662 could mask the presence of BC metastases in bone by inhibiting the differentiation of bone-resorbing osteoclasts. Nonetheless, metastatic miR-662-overexpressing BC cells then progressed as overt osteolytic metastases thanks to increased stem cell-like traits.ConclusionsMiR-662 is involved in BC metastasis progression, suggesting it may be used as a prognostic marker to identify BC patients at high risk of metastasis. |
| Document Type: |
article in journal/newspaper |
| File Description: |
ELETTRONICO |
| Language: |
English |
| Relation: |
info:eu-repo/semantics/altIdentifier/pmid/37443350; info:eu-repo/semantics/altIdentifier/wos/WOS:001029635800001; volume:129; issue:5; firstpage:754; lastpage:771; numberofpages:18; journal:BRITISH JOURNAL OF CANCER; https://hdl.handle.net/11567/1231818 |
| DOI: |
10.1038/s41416-023-02340-9 |
| Availability: |
https://hdl.handle.net/11567/1231818; https://doi.org/10.1038/s41416-023-02340-9 |
| Accession Number: |
edsbas.5F6F2CF4 |
| Database: |
BASE |